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Adeno-associated virus (AAV) capsid libraries have generated
improved transgene delivery vectors. We designed an AAV
library construct, iTransduce, that combines a peptide library
on the AAV9 capsid with a Cre cassette to enable sensitive detec-
tion of transgene expression. After only two selection rounds of
the library delivered intravenously in transgenic mice carrying a
Cre-inducible ﬂuorescent protein, we ﬂow sorted ﬂuorescent
cells from brain, and DNA sequencing revealed two dominant
capsids. One of the capsids, termed AAV-F, mediated transgene
expression in the brain cortexmore than 65-fold (astrocytes) and
171-fold (neurons) higher than the parental AAV9. High trans-
duction efﬁciency was sex-independent and sustained in two
mouse strains (C57BL/6 and BALB/c), making it a highly useful
capsid for CNS transduction of mice. Future work in large
animal models will test the translation potential of AAV-F.
INTRODUCTION
While adeno-associated virus 9 (AAV9) vectors have shown remark-
able potential for delivery to the CNS after systemic delivery, resulting
in clinical success in pediatric patients with spinal muscular atrophy,1
systemic injection of high doses of AAV vectors can lead to induction
of a T cell response that can eliminate transduced cells.2 In monkeys,
there is one report in which high systemic doses of anAAV9-like vector
resulted in toxicity and death of the animal, which was attributed to
systemic inﬂammation.3 A recent phase I clinical trial using high-
dose AAV9 to treat muscular dystrophy was placed on hold by the
US Food and Drug Administration (FDA) due to an immune reaction
after vector infusion in one patient. The reason high doses are required
is due to the relatively low efﬁciency of AAV on a per-vector genome
copy basis to provide adequate transgene expression in a substantial
number of target cells. Thus, developing new AAV capsids that allow
more efﬁcient transduction at lower doses should result in better ther-
apeutic efﬁcacy while lowering safety issues, such as immunotoxicity.
A promising approach to efﬁcient delivery of transgenes to target
cells is via a process of submitting a pool, or library, of AAV vector
capsids variants to an in vivo selection process, a veritable
“survival of the ﬁttest” approach.4–8 AAV library approaches
that use random oligomer nucleotides to insert short (6–9 aa)
random peptides into an exposed region on the capsid surface
have demonstrated success in identifying new AAV capsid variants
with unique properties such as enhanced transduction of target tis-
sues.9,10 One major limitation of AAV libraries is that the end
readout of the selection process does not always differentiate cap-
sids that mediate functional transgene expression from those that
do not. AAV transduction is a process involving multiple steps,
from cell receptor binding and entry to nuclear transport, sec-
ond-strand synthesis, and ﬁnally gene and protein expression.11
A recent advance on the conventional AAV library approach,
called CREATE, engineered a Cre-sensitive AAV genome that
enabled selectively isolated capsids that have successfully trafﬁcked
to the nucleus in the context of a Cre-expressing transgenic
animal.12 In this study, we describe a capsid selection system called
iTransduce in which we also utilize the power of the Cre/loxP sys-
tem. Instead of using Cre transgenic mice, we engineered the AAV
to encode capsids with peptide inserts, along with a Cre-expression
cassette. We then performed selection in mice with a Cre-sensitive
ﬂuorescent reporter to enable selection of capsids that mediate the
entire process of transduction, including transgene expression. We
show that in vivo selection of the library can result in the identi-
ﬁcation of an AAV capsid that mediates remarkable transduction
efﬁciency of the CNS.
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RESULTS
Design of iTransduce—An Expression-Based AAV Library
First, we constructed an AAV library plasmid that consisted of an
AAV2 inverted terminal repeat (ITR)-ﬂanked expression cassette
comprised of a chicken b-actin (CBA)-driven Cre recombinase and
a p41 promoter-driven AAV9 capsid (schematic in Figure 1A).
Pseudorandom 21-base nucleotides were inserted between AAV9
VP1 nucleotides encoding amino acids 588/589 via PCR. Before viral
packaging, we sequenced this plasmid library using low-depth next-
generation sequencing (NGS) and conﬁrmed the presence of
21-mer inserts in the vast majority of plasmids and the lack of variant
bias (data not shown). We then packaged the capsid library and per-
formed NGS to validate that the vector creation process maintained a
sufﬁcient diversity for selection. iTransduce relies on each unique
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Figure 1. iTransduce Library for Selection of Novel AAV Capsids Capable of Efficient Transgene Expression in Target Tissue
(A) Two-component system of the library construct. (1) Cre recombinase is driven by a minimal chicken b-actin (CBA) promoter. (2) p41 promoter-driven AAV9 capsid with
random heptamer peptide is inserted between amino acids 588 and 589, cloned downstream of the Cre cassette. (B) Selection strategy. (Bi) The iTransduce library
comprised of different peptide inserts expressed on the capsid (represented by different colors) is injected intravenously (i.v.) into an Ai9 transgenic mouse with a loxP-flanked
STOP cassette upsteam of the tdTomato reporter gene, inserted into the Gt(ROSA)26Sor locus. AAV capsids able to enter the cell of interest but that do not functionally
transduce the cell (no Cre expression) do not turn on tdTomato expression. Capsids that canmediate functional transduction (express Cre) will turn on tdTomato expression.
(Bii) Cells are isolated from the organ of interest (e.g., brain), and transduced cells are sorted for tdTomato expression and optionally cell markers. (Biii) Capsid DNA is PCR
amplified from the sorted cells, cloned back to the library vector, and repackaged for another round of selection. DNA sequencing analysis is utilized after each round to
monitor the selection process.
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capsid carrying both its own cap gene as well as a Cre-expressing
construct (Figure 1B). Transgenic mice (Ai9) carrying a ﬂoxed-
STOP tdTomato cassette are injected intravenously with the AAV
library (Figures 1Bi). Those capsids that successfully transduce cells
enable tdTomato expression in any target organ or cell type (without
being dependent on the availability of speciﬁc Cre transgenic mouse
lines); these tdTomato-positive cells can then be ﬂow sorted from the
tissue of interest (optionally, alongside cell-speciﬁc markers; Fig-
ure 1Bii). Viral DNA rescued from these cells should correspond to
capsid variants that can effectively overcome all of the extracellular
and intracellular biological barriers to transgene expression
(Figure 1Biii).
Selection of New AAV9 Capsid Variants Using Transgene
Expression to Identify Functional Capsids
To test the iTransduce library strategy, we performed a proof-of-
concept selection to attempt to isolate AAV capsid variants with
the ability to transduce brain cells after systemic injection. 1.27 x
1011 vector genomes (vg; 5  1012 vg/kg) of the library were injected
intravenously through the tail vein of one adult male and one female
Ai9 mouse, and 3 weeks postinjection the mice were killed; sections of
liver, brain, spleen, and kidney were cut and immunostaining of tdTo-
mato was performed. We readily detected tdTomato-positive cells
(likely hepatocytes) in the liver, with scattered tdTomato-positive
cells (both neurons and astrocytes) in the brain as well as the other
organs (Figure S1A). We also tested whether we could rescue the
cap DNA containing the 21-base insert by PCR, and we detected spe-
ciﬁc bands in 10 organs/tissues in mice injected with the library, but
not in control, non-injected mice (Figure S1B). We pooled the re-
maining brain tissue from the female and male mice, and DNA was
extracted, initially from total brain tissue for the ﬁrst round of
selection. We ampliﬁed cap DNA containing the 21-mer insert and
analyzed its identity and read counts using NGS. We observed sub-
stantial enrichment of speciﬁc peptides in the library population har-
vested from brain tissue following a single round of selection when
compared to the unselected library and with the variants retrieved
from liver (Figure S1C; data not shown). Next, we isolated the
insert-containing region of viral DNA and re-cloned it back into
the AAV plasmid backbone and repackaged capsids (“brain-enriched
capsid library”) for a second round of selection.
For the second round of selection, two Ai9 mice (one male, one
female) were injected with the library rescued from round 1 (dose
of 1.91  1010 vg, 7.64  1011 vg/kg) and sacriﬁced after 3 weeks.
Prior to injection, sequence containing the variant region was ampli-
ﬁed and sequenced by NGS to ensure that a preexisting bias had not
been introduced into the vector pool (Figure 2). The brain tissue was
dissociated to obtain a cell suspension for sorting tdTomato-positive
cells by ﬂow cytometry. We ﬂow sorted 3,834 tdTomato-positive cells
(0.043% of the initial cell suspension), which were indicative of suc-
cessful transduction (Figure S2). Viral DNA from tdTomato-sorted
cells was ampliﬁed and sequenced as previously done (Figure 2). Viral
DNA isolated from tdTomato-positive cells showed 97% of reads rep-
resented by just three peptides, STTLYSP, FVVGQSY, and FQPCP*
(where * indicates a stop codon) (Figure 2). We selected two of these,
STTLYSP (termed AAV-S) and FVVGQSY (termed AAV-F), for
Round 2 selection
(tdTomato-positive)
STTLYSP
0.46
FVVGQSY
0.30
FQPCP*
0.21
Others
0.03
B
Round 2 vector
(pre-injection)
Others, 0.48
A
P*,
Figure 2. Identification of AAV-S and AAV-F after Two Rounds of In Vivo Selection for Brain Transduction
Donut charts indicate the frequency of particular peptide inserts determined by NGS. (A) Chart of round 2 vector sequenced after production but before intravenous injection.
(B) Chart of peptide frequency appearing in iTransduce isolation after round 2 injection. “Others” indicates sequence variants appearing as less than 1% of the total pool (in A,
variants isolated after the round 2 screen are also highlighted, appearing at less than 1%). The asterisk (*) indicates a stop codon.
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functional evaluation in vivo (we excluded evaluation of FQPCP*, as it
was likely a product of cross-packaging). As seen in Figure 2, both of
these sequences were detectable in the round 2 library at low levels
(0.4% of reads for each variant), but they were highly enriched in
the brain after selection.
AAV-F Capsid Mediates Efficient Transgene Expression in the
Murine CNS
To test whether these peptides displayed on the capsid of AAV could
mediate efﬁcient transgene expression by an AAV vector, we pro-
duced these capsids (AAV-S and AAV-F), packaging a single-
stranded CBA promoter-driven GFP expression cassette (Figure 3A).
For comparison, we included the parental AAV9 vector and AAV9-
PHP.B, the most widely studied AAV9 variant with a 7-mer peptide
insertion (TLAVPFK) generated by directed evolution.12 All vectors
produced well and gave slightly lower production efﬁciencies than
did AAV9 (Table 1). Adult male C57BL/6J mice were injected via
the lateral tail vein with a low dose or a high dose (1  1011 vg and
8  1011 vg of vector, respectively; approximately 4  1012 and
3.2  1013 vg/kg) of one of the following vectors: AAV9, AAV9-
PHP.B, AAV-S, and AAV-F (n = 3 each). Three weeks postinjection,
mice were killed and organs harvested for endogenous (unstained)
GFP ﬂuorescence analysis. We quantitated the percent coverage of
the GFP signal in serial sagittal brain sections (three sections were
analyzed per animal). Remarkably, AAV-F demonstrated a 119-fold
(p < 0.0001) and 68-fold (p = 0.0004) increased GFP ﬂuorescence
coverage compared to the parental AAV9 vector at 1  1011 vg and
8  1011 vg, respectively (Figures 3B, 3C, 3E, and 3F; Figure S3).
AAV9 and AAV-S displayed similar GFP coverage levels (Figures
3B, 3C, 3E, and 3F). AAV9-PHP.B gave slightly higher GFP coverage
at the low dose compared to AAV-F, while similar levels of GFP
coverage were observed at the 8  1011 vg dose (Figures 3B, 3C, 3E,
and 3F). Similar to AAV9-PHP.B, AAV-F transduced the spinal
cord with remarkable efﬁciency (Figure 3D). Most areas of the brain
were effectively targeted by AAV-F, and a robust GFP signal was
observed in the cortex, hippocampus, striatum, cerebellum, and olfac-
tory bulb (Figure 3F).
In order to get a detailed appreciation of the cell types being targeted
by AAV-S and AAV-F, we next performed a series of co-immuno-
staining with GFP and markers of neurons (NeuN), astrocytes
(glutamine synthetase [GS]), microglia (Iba-1), and oligodendro-
cytes (Olig2). AAV-F and AAV-S, similar to the other two reference
vectors, mainly transduced neurons and astrocytes (none of the var-
iants appeared to effectively transduce microglial or oligodendrog-
lial cells; Figures 4A and 4B; data not shown). Stereological quanti-
tation of neurons and astrocytes in the cortex at the 1 1011 vg dose
conﬁrmed the efﬁcient transduction potential of AAV-F as
compared with conventional AAV9 by a factor of 65 in astrocytes
and 171 in neurons, while the difference between AAVS and
AAV9 was not signiﬁcant (the percent of GFP-positive astrocytes
was 0.63% ± 0.24% for AAV9 and 0.36% ± 0.15% for AAV-S, and
the percent of GFP-positive neurons was 0.039% ± 0.0.02% for
AAV9 and 0.029% ± 0.002% for AAV-S; all ± numbers represent
SEM). Of note, AAV-F targeted signiﬁcantly more astrocytes
(40.78% ± 0.73%) than AAV9-PHP.B (28.21% ± 0.25%), and the
reverse was true for neurons (6.67% ± 0.5% for AAV-F and
10.59% ± 0.16% for AAV9-PHP.B; Figure 4C), suggestive of a
slightly different tropism between those two vectors in mice. In
addition, AAV-F transduced a variety of neuronal sub-types,
including excitatory (CamKII-positive) and inhibitory (GAD67-
positive) cortical neurons, dopaminergic neurons in the striatum
(expressing tyrosine hydroxylase [TH]), Purkinje neurons in the
cerebellum (calbindin positive), and motor neurons in the spinal
cord (expressing the choline acetyltransferase [ChAT] marker; Fig-
ure S4A). Consistent with the stereological counts in the cortex (Fig-
ure 4C) and with the images of the high dose of AAV-F versus
AAV9 (Figure 3F), we observed efﬁcient transduction of
neurons and astrocytes with AAV-F and not AAV9 at the dose of
1  1011 vg/mouse in the striatum, hippocampus, and cerebellum
(Figure S4B).
To better understand whether the high levels of GFP transgene
expression in the brain with AAV-F corresponded to higher levels
of AAV genomes in the brain, we isolated vector andmurine genomic
DNA from liver and brain and performed qPCR on the 8  1011 vg-
dosed mice. AAV-F displayed a 20-fold enhancement (p < 0.0001) in
AAV genomes in the brain compared to AAV9 (Figure 4D). As re-
ported, AAV9-PHP.B had a much higher (25-fold) amount of AAV
genomes in the brain compared to AAV9, while AAV-S had a low
Table 1. Production Efficiency of AAV Capsids
AAV Capsid Titer (vg/mL) Production Efﬁciency (vg/Cell)
AAV9 3.20  1013 (±2.55  1013) 3.06  104 (±1.39  104)
AAV-F 5.51  1012 (±4.23  1012) 9.57  103 (±8.00  103)
AAV-S 1.88  1013 (1.38  1013) 2.09  104 (±5.65  103)
All capsids packaged a single-stranded AAV2 ITR-ﬂanked AAV-CBA-GFP-WPRE
transgene cassette.
Figure 3. AAV-F Efficiently Transduces the Brain of Mice after Systemic Injection
(A) Single-stranded AAV-GFP expression cassette used to compare the transduction potential of capsids. ITR, inverted terminal repeat; CBA, hybrid CMV enhancer/chicken
b-actin promoter; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element; pA, poly(A) signals (both SV40 and bovine growth hormone derived). (B)
Representative low-magnification images of whole-brain sagittal sections fromC57BL/6mice (males) transduced with 1 1011 vg (low dose) of AAV9, AAV9-PHP.B, AAV-S,
or AAV-F. (C) Representative images of sagittal section of brains after injection of 8  1011 vg (high dose) of each vector in C57BL/6 males. (D) Example sections of spinal
cords transduced by each of the four vectors administered intravenously at the higher dose (8 1011 vg/mouse). (E) Quantitation of native GFP expression from each vector
by the percentage of sections covered by fluorescence at low (left panel) and high (right panel) doses. (F) Multiregional comparison of transduction in the brain at the higher
dose. ***p < 0.001; ****p < 0.0001 after one-way ANOVA with Tukey’s multiple comparison test (n = 3 mice/group).
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Figure 4. AAV Vector Comparison of Neuron and Astrocyte
Transduction and Biodistribution
High-magnification images of AAV9-, AAV-PHP.B-, AAV-S-, and
AAV-F-transduced cells (GFP positive) after co-immunostaining with
markers for (A) neurons (NeuN) and (B) astrocytes (glutamine syn-
thetase [GS]). Merged cells also include nuclear staining by DAPI. (C)
Stereological evaluation of the percentage of transduced cortical
astrocytes and neurons after intravenous (i.v.) delivery of 1  1011 vg
of each vector. p < 0.0001 by one-way ANOVA. One (*) and two (**)
asterisks represent the significant differences between each vector
group after Tukey’s multiple comparisons test (n = 3 mice/group). (D)
Biodistribution of vectors in the brain and liver as measured by qPCR
of vector genomes, normalized by GAPDH genomic DNA levels (input
DNA). (E) Transduction of AAV9, AAV9-PHP.B, AAV-S, and AAV-F in
peripheral organs following intravenous administration at 8  1011 vg
in C57BL/6 males. Retinal images: RPE, retinal pigment epithelium;
ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner
nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer.
****p < 0.0001 (n = 3 mice/group, one-way ANOVA with Tukey’s
multiple comparisons test).
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level, similar to the GFP ﬂuorescence data (Figure 3). PHP.B showed
expression levels in the liver that were slightly lower than AAV9 and
AAV-F (although not AAV-S; Figure 4D). AAV-F showed levels in
the liver similar to AAV9, and AAV-S showed a lower, but nonsignif-
icant trend downward. We also examined the biodistribution of
AAV-F compared to AAV9 in several other organs, including skeletal
muscle, heart, and spinal cord (Figure S5).We observed no signiﬁcant
difference between the two vectors in muscle and heart (although an
upward trend was seen with respect to AAV-F in the heart). As would
be expected from expression in the brain, AAV-F showed signiﬁ-
cantly higher expression levels in the spinal cord compared to
AAV9 (p < 0.05, t test).
To investigate transgene expression in peripheral organs after sys-
temic injection, we analyzed GFP ﬂuorescence in the liver, heart, skel-
etal muscle, and retina (Figure 4E). Not surprisingly, all vectors trans-
duced liver efﬁciently. In the heart and skeletal muscle, AAV-S
yielded higher numbers of bright GFP signal/section than did
AAV9 and AAV-F. All capsids mediated low transduction of the
retina, as expected with intravenous delivery. Interestingly, while
AAV-9 and AAV-S did not transduce the neuronal retina, consistent
expression was observed in the retinal pigment epithelium (RPE).
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Figure 5. AAV-F Mediates High Transduction in Male
and Female C57BL/6 Mice and Also in BALB/c Mice
(A) Representative images of GFP signal across sagittal
brain sections in male and female mice (n = 3) transduced
by AAV-F at 1 1011 vg/mouse. (B) Sagittal brain sections
of male BALB/c mice injected with AAV-F (left) or AAV9-
PHP.B (right) at 1 1011 vg/mouse. DAPI (blue) is provided
as a counterstain alongside GFP (green) to visualize
PHP.B-treated brain sections. (C) Quantitation of native
GFP expression from each vector by the percentage of
sections covered by fluorescence. **p < 0.01. Unpaired
t test (n = 3 mice/group).
Both AAV9-PHP.B and AAV-F transduced mul-
tiple layers in the retina, most notably cells in the
ganglion cell layer (GCL). GFP expression was
also observed in the inner nuclear layer (INL),
with substantial expression shown in the outer
plexiform layer (OPL), which may reﬂect bipolar
or inhibitory horizontal cell transduction.
Since transduction by AAV vectors in mice can
vary substantially between sex and mouse strain,
we examined whether the most efﬁcient capsid,
AAV-F, could efﬁciently transduce brain after
systemic injection of female C57BL/6 as well
as male BALB/ mice. Mice were injected with
1  1011 vg (4  1012 vg/kg), and we observed
robust and efﬁcient transduction independent
of strain or sex (Figure 5). These results con-
trasted with the lack of efﬁcacy of AAV9-
PHP.B at transducing the CNS after systemic
delivery in the BALB/c strain, as previously reported (Figures 5B
and 5C).13,14
While iodixanol density gradient puriﬁcation removes most empty
capsids, to examine whether an excess of empty capsids in AAV-F
could explain its increased biodistribution to the brain compared to
AAV9, we performed transmission electron microscopy (TEM) on
two separate preparations of AAV-F and compared them to two inde-
pendent preparations of AAV9. As seen in Figure S6, we observed no
signiﬁcant difference in empty capsid levels between AAV-F and
AAV9 (mean 4.63% ± 1.99% versus 5.2% ± 2.18% empty capsids for
AAV9 and AAV-F respectively; mean ± SD; p = 0.54, unpaired t test).
Next, we tested whether AAV-F would have utility as a vector for CNS
transduction via other routes of administration. We ﬁrst tested AAV-
S and AAV-F to mediate transgene expression in the brain after direct
hippocampal injection of adult C57BL/6 mice. We found that both
capsids achieve a widespread expression of GFP after direct injection,
primarily in neurons (Figure S7). Intrathecal injection of AAV vectors
to transduce the spinal cord has shown promise to treat this compart-
ment. One drawback is limited spread of the vector to the brain after
lumbar injection of vector. We compared AAV9 and AAV-F after
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bolus intrathecal injection of vector into the lumbar region of the spi-
nal cord in adult C57BL/6 mice. Three weeks postinjection, mice were
killed and spinal cords and brains analyzed. Remarkably, AAV-F
resulted in much more intense GFP expression throughout the spinal
cord compared to AAV9, transducing both white and gray matter.
Meanwhile AAV9 transduction was mainly restricted to the white
matter. Strikingly, we also detected transduction of astrocytes and
neurons in the brain of mice injected with AAV-F, but not AAV9
(Figure S8).
AAV-F Mediates Enhanced Transduction of Human Neurons
Because the selection was performed in mice, we analyzed whether the
robust transduction characteristics of AAV-F also translated to human
cells. Primary human stem-cell-derived neurons were transduced with
equal doses of AAV9, AAV-S, and AAV-F, all encoding GFP. One
week later theywere ﬁxed, stainedwith class III b-tubulin, and analyzed
for the percentage of GFP-positive neurons. Remarkably, AAV-F
transduced 62% of neurons, 3-fold higher than AAV9 (p < 0.05) (Fig-
ure 6). AAV-S yielded a slight, yet statistically signiﬁcant (p < 0.05) in-
crease in transduction efﬁciency over AAV9 (Figure 6A).
DISCUSSION
Using the iTransduce system, we have isolated a new AAV capsid,
AAV-F, which mediates highly efﬁcient transgene expression in the
murine CNS (two strains tested). This capsid also mediated robust
transduction of primary human neurons.
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Figure 6. AAV-F Mediates Higher Transduction
Efficiency than AAV9 in Human Cortical Neurons
(A) GFP expression in fetal-derived primary human neu-
rons, transduced by AAV-F. Neurons were co-labeled with
an antibody to b-tubulin to quantify transduction. (B)
Quantitation of transduction efficiency of human neurons
by AAV9, AAV-S, and AAV-F. *p < 0.05.
Interestingly, using expression-based selection,
we identiﬁed three peptide clones (STTLYSP,
FVVGQSY, and FQPCP*) that represented
97% of NGS reads. Since FQPCP* had a stop
codon, we reasoned that this genome was
cross-packaged in another capsid during pro-
duction, a phenomenon noted to occur with
AAV libraries.15 This may also be the case
for STTLYSP (AAV-S) (Figure 2). AAV-S was
not a defective vector, however, as it mediated
robust transduction of peripheral organs (Fig-
ure 4E). Because it had such a high production
efﬁciency (Table 1), it may have had a propensity
to be cross-packaged. Alternatively, AAV-F
(FVVGQSY) was extremely efﬁcient at transduc-
tion and was one of only two prospective candi-
dates from the NGS (Figure 2). Both of these can-
didates were detectable at very low levels in the
round 2 library pool (Figure 2); as such, we could
conﬁrm that their enrichment was not due to a preexisting bias. We
do acknowledge that ﬂow-cytometry-based selection of tdTomato-
positive cells and subsequent PCR ampliﬁcation from this cell popu-
lation may have skewed the peptide population. The apparent “false
positives” of AAV-S and FQPCP* may have resulted from our use
of relatively high AAV plasmids/cell (100) during library produc-
tion in 293T cells, and in the future lower amounts may decrease
this issue. However, we consider identifying one highly efﬁcient
capsid (AAV-F) out of three candidates to be a successful selection.
Since we performed a demonstration of the iTransduce system using
an agnostic approach to cell type (whole brain), it is not surprising
that AAV-F was highly tropic to astrocytes and neurons, cells that
are transduced by AAV9. In future studies we will combine cell-
speciﬁc promoters to drive Cre expression from the AAV library
vector to isolate capsids that can transduce cells that are refractory
to conventional AAV vector transduction.
In addition to the potential of the iTransduce system to select clinical
candidate AAV vectors, it may be used to identify vectors for use as
research tools. The recently identiﬁed AAV-PHP.B capsid has served
as an efﬁcient vector to genetically modify the murine brain.12
However, it does not transduce BALB/c- or BALB/c-related mouse
lineages.13,14,16 Interestingly, we observed robust transduction of
BALB/c and C57BL/6 murine brain after intravenous injection of
AAV-F. This indicates that the mechanism of enhanced transduction
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over AAV9 differs between AAV-PHP.B and AAV-F. It also enables
AAV-F to be utilized as an efﬁcient tool for CNS research in the pop-
ular BALB/c strain (https://www.labome.com/method/Laboratory-
Mice-and-Rats.html). Additionally, we show that AAV-F can also
mediate robust transgene expression in the CNS after both direct
and intrathecal bolus injection.
While the results with AAV-F are very promising in mice, the true
translational potential of this vector remains to be observed. Future
studies in larger animals need to be carried out to test whether
AAV-F has potential clinically. Dose escalation studies should be per-
formed to test for dose-related toxicity of AAV-F, as was observed
with PHP.B in NHPs.14 Other strategies may be employed in the
near future to increase the chances of translational probability. First,
doing iterative rounds of selection in different species (e.g., mice, then
rats) may allow better cross-species translation of the transduction ef-
ﬁciency. This could be done in mice followed by ﬂoxed STOP
tdTomato transgenic rats.17 Alternatively, in the future, direct selec-
tion of the iTransduce library could be performed in transgenic
marmosets.18,19
MATERIALS AND METHODS
AAV Library Construction
iTransduce Plasmid: pAAV-CBA-Cre-mut-p41-Cap9del
We constructed the iTransduce library backbone plasmid called
pAAV-CBA-Cremut-p41-Cap9del, containing two expression cas-
settes in cis: (1) the CBA-Cremut, in which we introduced a mutant
Cre cDNA (CCG/CCT encoding the Pro15 amino acid to eliminate
the AgeI site initially present) under the ubiquitous promoter CBA;
and (2) the p41-Cap9del composed of the AAV9 capsid gene under
the AAV5 p41 promoter (residues 1680–1974 of GenBank:
AF085716.1) and splicing sequences of the AAV2 rep gene (similar
as described in Deverman et al.12).
Both the mutant Cre cDNA (Cremut) ﬂanked by KpnI and SalI restric-
tion sites and the p41-CAP9(del)-poly(A) fragment were synthesized
by GenScript and cloned into a puC57 backbone.We constructed ﬁrst
the pAAV-CBA-Cremut-poly(A) plasmid by subcloning the mutant
Cre cDNA (fragment KpnI-blunt, SalI) in place of EGFP-woodchuck
hepatitis virus post-transcriptional regulatory element (WPRE) in
our pAAV-CBA-WPRE backbone (opened with NcoI-blunt/SalI,
which eliminated the EGFP-WPRE fragment initially present). We
then introduced the p41-Cap9del fragment harboring a K449R muta-
tion in the Cap9 sequence, allowing the creation of a unique XbaI site,
and in which the 447-bp Cap sequence between XbaI and AgeI
restriction sites had been deleted.
Plasmid for Generating Random 7-mer Peptide Cap Fragments
and Subcloning the CAP9 Fragments Retrieved by PCR: pUC57-
Cap9-XbaI/KpnI/AgeI
We ﬁrst had the 447-bp region of the AAV9 capsid sequence between
the XbaI/AgeI sites (sequence that is missing in pAAV-CBA-Cremut-
p41-Cap9del) synthesized by GenScript (Piscataway, NJ, USA) and
subcloned into a pUC57-Kan plasmid. This capsid sequence contains
the same removal of the EarI site in this 447-bp region wild-type
(WT) AAV9 cap, which allows restriction digest removal of WT
AAV9 as described by Deverman et al.12 This also creates a unique
KpnI site. The cap fragment of pUC57-Cap9-XbaI/KpnI/AgeI was
used to generate the initial library of random 21-mer nucleotide se-
quences (encoding for 7-merpeptides) insertedbetweennucleotides en-
coding amino acids 588 and 589 of AAV9 VP3. We used a strategy
similar to that of Deverman et al.12 Brieﬂy, pUC57-Cap9-XbaI/KpnI/
AgeI served as template to amplify the cap DNA and insert random
21-mer sequences using a forward and reverse primer. The primer in-
formation was as follows: XF-extend (50-GTACTATCTCTCT
AGAACTATTAACGGTTC-30) and reverse primer 588iRev (50-GT
ATTCCTTGGTTTTGAACCCAACCGGTCTGCGCCTGTGCXMN
NMNNMNNMNNMNNMNNMNNTTGGGCACTCTGGTGGTT
TGTG-30), in which theMNN repeat refers to the randomized 21-mer
nucleotides (purchased from IDT). XF-extend and 588iRev were used
in a PCR with Phusion polymerase (NEB) and pUC57-Cap9-XbaI/
KpnI/AgeI as template. The 447-bp PCR product was digested with
XbaI and AgeI overnight at 37C and then gel puriﬁed (QIAGEN).
Similarly, pAAV-CBA-Cre-mut-p41-Cap9del was digested with XbaI
and AgeI and gel puriﬁed. Next, a ligation reaction (1 h at room tem-
perature) with T4 DNA ligase (NEB) was performed using a 3:1 cap
insert-to-vector molar ratio. The subsequent ligated plasmid was
called pAAV-CBA-Cre-mut-p41-Cap9-7-mer and contained a pool of
plasmids with random 7-mer peptides inserted in the cap gene
between nucleotides encoding 588 and 589 of AAV9 VP3.
This plasmid (pUC57-Cap9-XbaI/KpnI/AgeI) was also used as our
recipient plasmid for subcloning the CAP9 fragments ampliﬁed by
PCR from brain tissue. We removed an upstream KpnI site in the
pUC57 plasmid by digestion with SacI and NsiI and ligation. This
allowed the KpnI site in the capsid fragment to be unique.
Rep Expression Plasmid
We constructed a rep expression plasmid called pAR9-Cap9-stop/
AAP/Rep using a similar strategy to that as Deverman et al.12 The
entire cDNA was synthesized by GenScript and cloned into a
pUC57-Kan plasmid. Stop codons were inserted in place of start
codons for VP1, VP2, and VP3 so that no parental AAV9 capsids
were produced, while maintaining AAP and rep expression.
AAV Library Production and Purification
For each production, we plated 15-cm tissue culture dishes (usually
10-15 dishes total) with 1.5  107 293T cells/dish. The next day cells
were transfected using the calcium phosphate method, with the
adenovirus helper plasmid (pAdDF6, 26 mg per plate), rep plasmid
(pAR9-Cap9-stop/AAP/Rep, 12 mg per plate), and ITR-ﬂanked
AAV library (pAAV-CBA-Cre-mut/p41-Cap9-7-mer, 1 mg per plate)
to induce production of AAV. The day after transfection, medium
was changed to DMEM containing 2% fetal bovine serum (FBS).
AAV was puriﬁed from the cell lysate using iodixanol density-
gradient ultracentrifugation. Buffer exchange to PBS was done using
Zeba spin columns (7 K molecular weight cutoff [MWCO]; Thermo
Fisher Scientiﬁc), and further concentration was performed using
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Amicon Ultra 100 kDa MWCO ultraﬁltration centrifugal devices
(Millipore). Vectors were stored at 80C until use. We quantiﬁed
AAV genomic copies (vg) in AAV preparations using TaqMan
qPCR with ITR-sequence-speciﬁc primers and probes.20,21
NGS of Library
NGS was performed on the plasmid AAV9 library pool, as well as
following packaging of capsids. Sequencing was also performed
following PCR rescue of the cap fragment (either from brain
tissue or from isolated tdTomato-positive cells sorted by ﬂow
cytometry). For each round of selection, viral DNA corresponding
to the insert-containing region was ampliﬁed by PCR using Q5
polymerase from New England Biolabs (forward primer, 50-AA
TCCTGGACCTGCTATGGC-30; reverse primer, 50-TGCCAAAC
CATACCCGGAAG-30). Unique barcode adapters were annealed to
each sample, and samples were sequenced on an Illumina MiSeq
(150 bp reads). Approximately 50–100,000 reads per sample were
analyzed. Sequence output ﬁles were quality checked initially
using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/
fastqc/) and analyzed on a program customwritten in Python. Brieﬂy,
sequences were binned based on the presence or absence of insert;
insert-containing sequences were then compared to a baseline refer-
ence sequence, and error-free reads were tabulated based on inci-
dences of each detected unique insert. Inserts were translated and
normalized.
Animals
All animal experiments were approved by the Massachusetts General
Hospital Subcommittee on Research Animal Care following guide-
lines set forth by the National Institutes of Health Guide for the
Care and Use of Laboratory Animals. We used adult age (8–10 weeks
old) Ai9 (strain no. 007909), C57BL/6 (strain no. 000664), and BALB/
c (strain no. 000651) mice, all from The Jackson Laboratory (Bar
Harbor, ME, USA). All animals were euthanized 3 weeks postinjec-
tion, perfused transcardially, and tissues were harvested and either
ﬁxed in 4% paraformaldehyde in PBS, snap frozen in liquid nitrogen,
or dissociated for ﬂow cytometry.
In Vivo Selection of Brain-Tropic Capsids
Ai9 mice were injected intravenously (tail vein) with the dose in vg
indicated in the Results section, and 3 weeks postinjection, mice
were euthanized and tissue was harvested.
Mice were deeply anesthetized by isoﬂurane and decapitated. For
round 1, the brain was rapidly dissected and two coronal sections
(2 mm thick) were harvested. One section was used for extracting
whole-brain DNA (DNeasy blood and tissue kits, QIAGEN, Hilden,
Germany). The other coronal section was ﬁxed in 4% PFA and
parafﬁn embedded for immunohistology (tdTomato-positive cells
were detected after each round of selection by diaminobenzidine
[DAB] staining using a rabbit anti-red ﬂuorescent protein [RFP] anti-
body from Rockland Immunochemicals). For round 2, brain tissue
was then cut with a razorblade into 1-mm3 pieces and neural cells
were isolated by papain dissociation (papain dissociation system,
Worthington Biochemical), according to the manufacturer’s instruc-
tions. Following dissociation, myelin was removed (Myelin Removal
Beads II, human, mouse, rat from Miltenyi) and the tdTomato-posi-
tive cells were sorted by a S3e cell sorter (Bio-Rad). Cells were sorted
by ﬁrst setting gates to exclude cellular debris and select for singlets
only. Cell suspensions from an AAV9-PHP.B-Cre-injected Ai9
(positive control) and a PBS-injected Ai9 mouse (negative control)
were used to set gates to sort tdTomato-positive and tdTomato-nega-
tive cells. After sorting, the tdTomato-positive cells were immediately
pelleted by centrifugation, and DNAwas extracted using the Arcturus
PicoPure DNA extraction kit (Thermo Fisher).
After DNA extraction, the Cap9 inserts (containing the 21-mer
sequence encoding the 7-mer peptides) were ampliﬁed using
the following primers: Cap9_Kpn/Age_For: 50-AGCTACCGACA
ACAACGTGT-30 and Cap9_ Kpn/Age_Rev: 50- AGAAGGGTGA
AAGTTGCCGT-30 (Phusion high-ﬁdelity PCR kit, New England
Biolabs). The amplicons were then puriﬁed (Monarch PCR and
DNA cleanup kit, New England Biolabs), digested by KpnI, AgeI,
and BanII, and the Cap9 KpnI-AgeI fragments (144 bp) were agarose
gel puriﬁed (Monarch DNA gel extraction kit, New England Biolabs)
before ligation in the pUC57-Cap9-XbaI/AgeI/KpnI plasmid (opened
with KpnI and AgeI and dephosphorylated with calf inositol phos-
phatase, New England Biolabs). The ligation products were trans-
formed into electrocompetent DH5a bacteria (New England Biolabs),
and the entire transformation was grown overnight in Lysogeny broth
(LB)-ampicillin medium. pUC57-Cap9-XbaI/AgeI/KpnI plasmid was
puriﬁed by Maxi Prep (QIAGEN). Plasmid was digested by XbaI/
AgeI to release the 447-bp cap fragment, which was gel puriﬁed
and ligated with similarly cut pAAV-CBA-Cre-mut/p41-Cap9del
for the next round of AAV library production.
AAV rep/cap Plasmids Containing AAV-F and AAV-S Peptide
Inserts for Vector Production
To create rep/cap plasmids encoding AAV9 capsids displaying the
peptide insert of interest for production of vectors encoding a trans-
gene of interest (e.g., GFP), we digested an AAV9 rep/cap plasmid
with BsiWI and BaeI, which removes a fragment ﬂanking the VP3
amino acid 588 site for peptide sequence insertion. Next, we ordered
a 997-bp dsDNA fragment from Integrated DNA Technologies (IDT,
Coralville, IA, USA), which contains overlapping Gibson homology
arms with the BsiWI/BaeI cut AAV9 as well as the 21-mer nucleotide
sequence encoding the peptide of interest in frame after amino acid
588 of VP3. Lastly, we performed Gibson assembly using the Gibson
Assembly master mix (NEB, Ipswich, MA, USA) to ligate the peptide-
containing insert into the AAV9 rep/cap plasmid. Sequence integrity
of the plasmid was determined by whole-plasmid sequencing.
AAV Vectors for Transduction Analysis
For each production, we plated 15-cm tissue culture dishes with
1.5  107 293T cells/dish. The next day cells were transfected using
the calcium phosphate method, with the adenovirus helper plasmid
(pAdDF6, 26 mg per plate), rep/cap plasmid (AAV9, AAV-F,
AAV-S, 12 mg per plate), and ITR-ﬂanked transgene cassette plasmid
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(single-stranded AAV-CBA-GFP-WPRE,22 10 mg per plate) to induce
production of AAV. The day after transfection, medium was changed
to DMEM containing 2% FBS. AAV was puriﬁed from the cell lysate
using iodixanol density-gradient ultracentrifugation. Buffer exchange
to PBS was done using Zeba spin columns (7 kDa MWCO; Thermo
Fisher Scientiﬁc), and further concentration was performed using
Amicon Ultra 100 kDa MWCO ultraﬁltration centrifugal devices
(Millipore). Vectors were stored at 80C until use. We quantiﬁed
AAV genomic copies in AAV preparations using TaqMan qPCR
with bovine growth hormone (BGH) poly(A)-sequence speciﬁc
primers and probe.23
Animal Euthanasia and Tissue Harvesting
Mice (strain indicated in each ﬁgure) were slowly injected via the
lateral tail vein with 200 mL of the tested AAV vector diluted in ster-
ile PBS (low dose, 4  1012 vg/kg; high dose, 3.2  1013 vg/kg)
before gently ﬁnger clamping the injection site until bleeding
stopped. Three weeks after injection, mice were euthanized and
perfused transcardially with sterile cold PBS. Next, the brain was
longitudinally bisected into two hemispheres. One hemisphere
was postﬁxed in 15% glycerol/4% paraformaldehyde diluted in
PBS for 48 h, followed by 30% glycerol for cryopreservation for
another 48–72 h. The other half was fresh frozen for isolation of
genomic and vector DNA. For the high-dose cohort, a small piece
of heart, muscle (gastrocnemius), and the retina were also processed
for immunohistology. We have made three independent prepara-
tions of AAV-S, AAV-F, and AAV9 (Table 1). The transduction
results in mice were from one preparation of each vector; however,
we have replicated these results in two more independent
experiments.
Immunohistology and High-Magnification Imaging of AAV-CBA-
GFP-Transduced Neural and Neuronal Cell Populations
Coronal ﬂoating sections (40 mm) were cut using a cryostat micro-
tome. After rinsing off the glycerol in Tris-buffered saline (TBS)
buffer, cryosections were permeabilized with 0.5% Triton X-100
(AmericanBio) in TBS for 30 min at room temperature and blocked
with 5% normal goat serum (or normal donkey serum) and 0.05%
Triton X-100 in TBS for 1 h at room temperature. Primary antibodies
were incubated overnight at 4C in 2.5% normal goat serum and
0.05% Triton X-100 in TBS, while Alexa Fluor 488- or Cy3-conju-
gated secondary antibodies (Jackson ImmunoResearch Laboratories,
Baltimore, MD, USA) were incubated for 1 h the next day. Primary
antibodies used for this study were: chicken anti-GFP (Aves Labs, Ti-
gard, OR, USA); mouse anti-NeuN (Millipore, Burlington, VT, USA);
rabbit anti-GS (Abcam, Cambridge, MA, USA); rabbit anti-Olig2
(Millipore, Burlington, VT, USA); rabbit anti-Iba1 (Wako, Japan);
rabbit anti-CamKII (Abcam, Cambridge, MA, USA); mouse anti-
GAD67 (Millipore, Burlington, VT, USA); rabbit anti-ChAT
(Millipore, Burlington, VT, USA); mouse anti-calbindin (Abcam,
Cambridge, MA, USA); and rabbit anti-TH (Novus Biologicals, Little-
ton, CO, USA). Sections were mounted with Vectashield mounting
medium with DAPI (Vector Laboratories, Burlingame, VT, USA).
To identify the neural cell types transduced by each vector and inves-
tigate the various neuronal subtypes targeted by AAV-F, a Zeiss Axio
Imager Z epiﬂuorescence microscope equipped with AxioVision soft-
ware and a 60 objective was used to take high-resolution images
showing colocalization between GFP and each cell marker.
Imaging and Quantification of Global GFP Signal Coverage
To quantify the overall native GFP ﬂuorescence signal in brain and
liver sections, a robotic slide scanner virtual slide microscope
VS120 (Olympus) was used to image the entire batch of slides on
one go using an Olympus UPLSAPO 10 objective. In order to
reduce variability, the entire batch of slides was imaged in one session.
The initial exposure time for GFP was set up so that the ﬂuorescent
signal was neither undersaturated nor oversaturated across all exper-
imental groups and remained unchanged throughout the entire batch
scan. The order of the slides was randomized and remained blinded
until ﬁnal statistical analysis. The Olympus cellSens Standard soft-
ware was then used to analyze the percentage of GFP coverage in
each brain section. A region of interest (ROI) was initially deﬁned us-
ing the “ROI-polygon” tool, and we quantiﬁed the GFP-positive area
within this initial ROI, after applying a similar detection threshold on
the GFP channel for all of the slides analyzed (the threshold was set at
a similar level for the analysis of all mouse brain sections, but a
different threshold was applied for the analysis of all mouse liver sec-
tions and all rat brain sections). The percentage of GFP-positive area
accordingly to the total surface of the ROI was then calculated. The
autoﬂuorescence signal was taken into account in our analysis, as
we set the threshold for EGFP ﬂuorescence intensity above the auto-
ﬂuorescence level (making sure that only the signal from AAV-GFP-
transduced cells was taken into account). In addition, we drew each
ROI for each brain section avoiding the very edges of the section,
as those could also present with a high level of autoﬂuorescence.
The ventricular space was also excluded from our analysis. Finally,
three technical replicates (brain sections) were measured per mouse
and all measurements were done blinded until the ﬁnal step of the
analysis.
Stereology-Based Quantitative Analyses of the Percentages of
Transduced Astrocytes and Neurons
Stereology-based studies were performed as previously described,24,25
after co-staining the brain sections for GFP and NeuN (neuronal
marker) or GFP and GS (pan-astrocytic marker). We did not include
microglia and oligodendrocytes in this analysis, as those cell types
were not transduced to an appreciable amount. Stereological evalua-
tion of the percentages of AAV-transduced neurons and astrocytes
was done blindly after de-identiﬁcation of the vector initially injected,
using a motorized stage of an Olympus BX51 epiﬂuorescence micro-
scope equipped with a DP70 digital CCD camera, an X-Cite ﬂuores-
cent lamp, and the associated CAST stereology software version
2.3.1.5 (Olympus, Tokyo, Japan). The cortex was initially outlined un-
der the 4 objective. Random sampling of the selected area was
deﬁned using the optical dissector probe of the CAST software. To
evaluate the percentage of AAV9-, AAV9-PHP.B-, AAV-S-, and
AAV-F-transduced astrocytes or neurons, the stereology-based
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counts were performed under the20 objective, with ameander sam-
pling of 10% for the surface of cortex for the “high transduction”
AAVs, and 20% for “low transduction” AAVs (considering the infre-
quency of GFP-positive cells in those cases). For each counting
frame, the total numbers of astrocytes (GS-positive cells) or neurons
(NeuN-positive cells) were evaluated, and, among each of those pop-
ulations, the percentages of GFP-positive cells were determined. Only
glial and neuronal cells with a DAPI-positive nucleus within the
counting frame were considered.
Vector Genome Quantification in the Brain and Liver
One brain hemisphere and a small piece of liver were fresh frozen for
AAV genome isolation for vector genome biodistribution. For the
fresh-frozen brain and liver samples, we isolated genomic and
AAV vector DNA from 10 mg of tissue using the DNeasy blood
and tissue kit (QIAGEN) according to manufacturer’s instructions.
DNA was quantitated using a NanoDrop ND-1000 spectrophotom-
eter (Thermo Scientiﬁc). Next, using 50 ng of genomic DNA as tem-
plate, we performed a TaqMan qPCR using probe and primers to the
poly(A) region of the transgene expression cassette (same assay used
to titer the puriﬁed AAV vectors). To ensure equal genomic DNA
input for each sample, we performed a separate qPCR on each
sample using a TaqMan probe and primer set that detects
GAPDH genomic DNA (Thermo Fisher Scientiﬁc, assay ID
Mm01180221_g1, gene symbol Gm12070). For each organ/tissue,
we adjusted the AAV vector genome copies for each sample by tak-
ing into account any differences in GAPDH threshold cycle (Ct)
values using the following formula: (AAV vector genome copies)/
(2DCt). The DCt value was calculated by the following formula:
GAPDH Ct value of sample of interest  average GAPDH Ct value
of sample that had the lowest amount of GAPDH (highest Ct value).
Data were expressed as AAV vector genomes per 50 ng of genomic
DNA.
Human Neuron Transduction
Primary human fetal neural stem cells (NSCs) were obtained from the
Birth Defects Research Laboratory (University of Washington,
Seattle, WA, USA) in full compliance with the NIH ethical guidelines.
The isolation procedure has been detailed previously26 with slight
modiﬁcations. Brieﬂy, brain tissue was incubated in 0.25% trypsin,
DNase (90 U/mL), diluted in Hank’s balanced salt solution (HBSS)
for 45 min. Tissue was titrated, transferred into 4C heat-inactivated
FBS, and centrifuged at 500  g for 20 min. The pellet was resus-
pended in NSC complete media consisting of X-VIVO 15 (without
phenol red and gentamicin; Lonza) supplemented with 10 mg of basic
ﬁbroblast growth factor (Life Technologies), 100 mg of epidermal
growth factor (Life Technologies), 5 mg of leukemia inhibitory factor
(Millipore), 60 ng/mL N-acetylcysteine (Sigma-Aldrich), 4 mL of
neural survival factor-1 supplement (Lonza), 5 mL of 100 N-2 sup-
plement (Life Technologies), 100 U of penicillin, 100 mg/mL strepto-
mycin (Life Technologies), and 2.5 mg/mL Fungizone (Life Technol-
ogies). Supernatants were then ﬁltered through a 40-mm cell strainer
(Corning Life Sciences). Neurospheres larger than 40 mm in diameter
were dissociated with Accutase (10 min). Neural differentiation me-
dium consisted of 1 neurobasal medium, 2% B-27 serum-free sup-
plement, and 2 mM GlutaMAX-I supplement (all from Invitrogen)
and supplemented with human recombinant brain-derived neurotro-
phic factor (BDNF) (10 ng/mL; PeproTech).
Differentiating NSCs were grown in chamber slides in differentiation
media for 2 weeks and then treated with the indicated AAV vector en-
coding GFP (7  109 vg/well added, 150 vg/cell). One week after
transduction, cells were ﬁxed with 4% paraformaldehyde and
permeabilized with 0.05% Triton X-100 (Sigma-Aldrich) in 1 PBS
(Invitrogen). Cells were stained with a primary monoclonal antibody
(TU-20) to neuron-speciﬁc class III b-tubulin (1:50; Abcam). Second-
ary antibodies conjugated to Alexa Fluor 594 (diluted 1:200;
Invitrogen) were added for 1 h, followed by DAPI for 30 min.
The slides were then mounted with a ProLong antifade reagent
(Invitrogen). Maximum projection images were generated from
captured z stacks using the Nikon A1R confocal microscope.
The z stacks were loaded in Imaris, and the surface module was used
to render the images into 3D volumes. GFP+ neurons were counted
(under channel 1, green), as were class III b-tubulin-positive neurons
(under channel 2, red). Using the Imaris colocalization module, the
population of neurons double positive for the above was determined.
Statistics
Statistical analysis of data was performed using GraphPad Prism
software (version 8.00). A one-way ANOVA test followed by a
Tukey’s multiple comparisons test was performed, across the different
groups AAV9, AAV9-PHP.B, AAV-S, and AAV-F. A value of
p < 0.05 was considered to be statistically signiﬁcant. Results are
shown as the mean ± SEM. Similar analyses were performed to
analyze the biodistribution of AAV genomes in brain and liver, as
well as transduction of human neurons.
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